Stop the pain: Tips for increasing patient retention and decreasing missing data in analgesia clinical trials
Rho
| « Previous month | Next month » |
Outsourcing.com would like to wish all our readers a happy holiday
It seems partnerships have made headlines almost every day in 2011, with more companies joining forces to align their expertise. Here’s the stories you wanted to see…
Contract testing services supplier LabCorp has secured a credit facility with the Bank of America, citing capital expenditures and acquisitions among the potential uses of the funds.
Outsourcing-Pharma presents its weekly round-up of the latest appointments within the pharmaceutical industry, including news from Patheon, Cetero and Roche.
Electroporation is the wave of the future for transdermal drug delivery, according to Parexel’s Ravi Harapanhalli.
BASi is optimistic Gilead Sciences’ $11bn acquisition of Pharmasset, the CRO’s biggest client, will be positive for the business.
Lonza has expanded small molecule production capacity at its plant in Nansha, China to meet demand for clinical trial materials.
Europe’s Innovative Medicines Initiative (IMI) has adopted the Clinical Data Interchange Standards Consortium’s (CDISC) standards for all future projects in a move announced this week.
Warnex is to sell its analytical services division to an unnamed private company in the latest move in a drastic restructuring programme.
PBI has inked a deal with Clinigene to establish a presence in India for its biomarker and laboratory services.
BASi posted its first full year net profit since 2007, despite a fourth quarter loss, and is seeking to expand its services with acquisitions.
DSM Biologics will work with the Australian Institute for Bioengineering and Nanotechnology (AIBN) on the commercialisation of development-stage biologics projects.
Quintiles says its alliance with Intarcia Therapeutics – developer of an injection-free diabetes drug – uses a financing model that could replace “old-fashioned” outsourcing business relationships.
Patheon posted a fourth quarter operating loss as costs related to restructuring offset an uptick in revenues.
Outsourcing clinical research may limit innovation and create opportunities for smaller competitors, research found.
Indian clinical trial start up times will return to normal early next year after becoming longer and inconsistent in 2011, Quintiles said.
Frontage Laboratories has teamed up with Janssen Pharmaceuticals to develop a chromatographic preclinical testing method they say could finally solve metformin development issues.
New Asian CRO Alliance (ACA) can offer faster and better decision making than multinational CROs says Semler Research Centre's clinical development VP.
An individual investor has bought Florida-based CRO Crystal3 Labs and changed the name of the company.
AIT Bioscience says its new alliance with Perfinity Biosciences will provide protein analysis in 10 minutes, rather than the 48 hours that is standard across the industry.
Six Asian CROs have set up a regional network and claim their local knowledge will make conducting clinical trials in the region more straightforward.
LabCorp has finally been cleared to buy DNA testing services firm Orchid Cellmark after the US Federal Trade Commission (FTC) OKed the deal, albeit, with some conditions.
Charles River wants to buy drug discovery assets to meet interest in strategic outsourcing of non-regulated efficacy testing.
Prestwick Chemical and Pharma Plexus Holland have set up a lead optimisation services collaboration intended to meet industry demand for larger candidate selection projects.
Outsourcing-Pharma presents its latest round-up of the comings and goings in the pharmaceutical sector, with breaking news from PPD whose CEO Raymond Hill has departed.
Quintiles hopes to build up its China-based study portfolio through its new contract research organisation (CRO) Kun Tuo.
Biopharm companies prefer outsourcing ECG work to specialist service providers than large CROs, an industry survey found.
Canadian contract testing firm Warnex has sold its medical lab division to Gamma-Dynacare Medical Laboratories as part of an ongoing strategic review.
Charles River Laboratories’ (CRL) preclinical division will continue to struggle in 2012 but the recent uptick in strategic partnership activity is a ray of hope according to a leading analyst.
Quotient has stressed the importance of screening prototype formulations early in the development process to ensure efficient drug delivery in later phases.
AmorChem Financial says its new contract research organisation (CRO) - set up to support in-house development - has spin-out potential.
Ireland-based CRO Icon says acquisition of Chinese trial firm BeijingWits Medical Consulting will boost capabilities in the country and help meet growing demand from global clients.
Oncology-focused CRO Acorn Research and diagnostic technology supplier Clarient have teamed up to set up testing procedures for common cancers.
In September Outsourcing-pharma held Patient Recruitment Outsourcing (PRO) in Boston, bringing together the movers and shakers in the recruitment sector. Robert Loll, vice president of business development, shares his thoughts on the event with a particular focus on the fantastic interactive discussion the he led at the end of the first day.
Sponsor and CRO perceptions of the quality of outsourced service provision differ markedly according to a study by consulting and survey research organisation, the Avoca Group.
Outsourcing-Pharma presents its round up of the latest new appointments within the pharmaceutical industry, including news from Tgas, ACRO and Camargo.
US contract research services organisation (CRO) CRI Worldwide has rebranded as CRI Lifetree.
Lonza will supply preclinical immunogenicity testing services for a candidate protein antiviral being worked on by South Korean biotech ImmuneMed.
Catalent says it will increase biologics capacity, joining the growing list of contractors investing in biodrug production.
Outsourcing-Pharma presents its round-up of the latest contract manufacturing updates, including news from Hospira, Aveo, and Shasun.
Clinical supply chains dominated the concerns of the service sector this week with Almac and Marken both launching new management solutions.
Warnex says the resignation of CEO Mark Busgang last week was a mutual decision and will not impact its ongoing review.
Clinical Network Services (CNS) has launched its new custom-fit regulatory consulting service, BioDesk.
Samsung will set up a $300m biosimilars development JV with Massachusetts, US-based Biogen Idec, building on the partnership it forged with CRO Quintiles earlier this year.
Cincinnati, US-based Schulman Associates Institutional Review Board (IRB) has bought Florida counterpart Independent Investigational Review Board (IIR) to broaden its offering for Pharmas and CROs.
Simplifying clinical trial eligibility criteria and reducing the number of recorded variables can cut risk of data fraud, statisticians said.
UBC & Medco are calling for personalised medicine developers to engage payers in Phase I to ensure necessary data is generated.
Quintiles has expanded its patient sample testing partnership with Indonesian firm Prodia Clinical Laboratory.
The global contract manufacturing market may be showing signs of recovery but careful investment and focusing on core activities is still the most sensible approach according to Sweden-based CDMO Recipharm.
UPS is to acquire Italy-based Pieffe Group to expand its European healthcare distribution network.
Biologics Modular is leasing its mobile production facilities to help clients make FDA regulated drugs without fixed plants.
Pharma companies and contract research organisations will soon be able to view important UK health data.
PPD shareholders have cleared the way for private equity firms to buy the CRO by voting in favour of the takeover.
Quintiles expects to make more investments in Asia-Pacific partnerships as the local biopharm sector grows.
| « Previous month | Next month » |